A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

BACKGROUND. We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients with recurrent glioblastoma who had progressed after first‐line treatment with radiotherapy, temozolomide, and BEV. PATIENTS AND METHODS. TAMIGA (NCT01860638) was a phase II, randomized, double‐bl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Brandes, Alba A., Gil‐Gil, Miguel, Saran, Frank, Carpentier, Antoine F., Nowak, Anna K., Mason, Warren, Zagonel, Vittorina, Dubois, François, Finocchiaro, Gaetano, Fountzilas, George, Cernea, Dana Michaela, Chinot, Oliver, Anghel, Rodica, Ghiringhelli, Francois, Beauchesne, Patrick, Lombardi, Giuseppe, Franceschi, Enrico, Makrutzki, Martina, Mpofu, Chiedzo, Urban, Hans‐Joerg, Pichler, Josef
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Neuro‐Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459244/
https://ncbi.nlm.nih.gov/pubmed/30266892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados